As an important step in the prevention of COVID-19, Pfizer-BioNTech submitted an application for authorization of their COVID-19 vaccine for use in children ages 5 to 11 years. On October 29, the Food and Drug Administration (FDA) authorized the emergency use of the vaccine for the prevention of COVID-19 in this pediatric population based on a thorough evaluation of data and input from the advisory committee of experts who voted in favor of making the vaccine available.
Join NACCHO for a webinar on Tuesday, November 9, 3:00-4:15 PM ET to receive updated information regarding approval, guidelines, and recommendations for pediatric COVID-19 vaccine. A CDC representative will join the discussion to present on the high-level outcomes of the FDA and CDC’s advisory committee meetings as well as an overview of the pediatric vaccine operational planning guide. Additionally, representatives from Pfizer will join to provide information on product packaging, shipping and storage, preparation, administration, adverse event reporting, and resources specific to the pediatric vaccine.
Note: This webinar will not be recorded but resources will be available afterwards.
